Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Trilogy International Partners Inc T.TRL.WT.A


Primary Symbol: V.TRL.H

Trilogy International Partners Inc. operates through its subsidiary Trilogy International Partners LLC (Trilogy LLC). Prior to the disposal of its New Zealand and Bolivia operations, Trilogy LLC was a provider of wireless voice and data communications services including local, international long distance and roaming services. Trilogy LLC also provided fixed broadband communications services to residential and enterprise customers in New Zealand and Bolivia. The Company had two reportable segments identified by their geographic regions, New Zealand and Bolivia. Two Degrees Mobile Limited (2degrees) operated in New Zealand and Empresa de Telecomunicaciones NuevaTel (PCS de Bolivia), S.A. (NuevaTel) operated in Bolivia. Both these segments provided a variety of wireless voice and data communications services, including local, international long distance and roaming services. The services were provided to subscribers on both a postpaid and prepaid basis.


TSXV:TRL.H - Post by User

Post by MelnykWasRighton Jul 11, 2018 1:13pm
145 Views
Post# 28300758

(ASP) EPS Estimated At $-0.04

(ASP) EPS Estimated At $-0.04
https://thecasualsmart.com/2018/07/07/acerus-pharmaceuticals-corporation-asp-eps-estimated-at-0-04/

Analysts expect Acerus Pharmaceuticals Corporation (TSE:ASP) to report $-0.04 EPS on August, 10.They anticipate $0.03 EPS change or 300.00 % from last quarter’s $-0.01 EPS. After having $-0.03 EPS previously, Acerus Pharmaceuticals Corporation’s analysts see 33.33 % EPS growth. It closed at $0.25 lastly. It is down 0.00% since July 7, 2017 and is . It has underperformed by 12.57% the S&P500.
Bullboard Posts